Debra J. Wilson

TL;DR: While the cell(s) responsible for activation and expression of LAK activity have some common features with the classic T cell-mediated CTL and NK cell systems, the LAK precursor cells are clearly distinct as determined by phenotype analysis using monoclonal antibodies and complement, and at present must be classified as a “null” cell.

TL;DR: Purified interleukin 2 (IL-2) was found to be sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer (LAK) cells and no other cytokines have been found that perform the same role.

TL;DR: The tumor selective killing of the LAK cells used for these treatments was demonstrated by their ability to lyse glioma cells but not normal cells in vitro using a chromium release microcytotoxicity assay.

TL;DR: These studies demonstrated that large numbers of PHA‐activated PBL can be safely obtained and infused into humans, achieving an increase in the number of circulating activated cells with evidence of migration of cells to tumor, lungs, liver and spleen.

TL;DR: The wide therapeutic window, extreme potency, and general applicability of this antibody-toxin conjugate against CSF-borne primary or metastatic tumors warrants clinical trials.